Biomx (PHGE) Stock Price

Biomx Price

NYSE AMEX·CLOSED
0.29
​
Market closed

For Biomx, the net margin of 7,330.3% is down versus 21,132.1% a few years ago.

Biomx stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomx business model & stock analysis

Biomx Inc, trading under the ticker PHGE, is a biotechnology company headquartered in Ness Ziona, Israel. The company focuses on developing bacteriophage-based therapies to address diseases caused by microbiome dysbiosis. Biomx Inc's approach combines natural and engineered phage solutions to target harmful bacteria affecting skin conditions and chronic diseases such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC), and cancer. The company identifies and validates bacterial targets, then customizes phage compositions to combat these targets. Biomx Inc's pipeline includes three product candidates: BX001, designed to improve acne-prone skin appearance; BX002, a customized phage cocktail targeting bacterial causes of IBD; and BX003, a phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp). Founded through an IPO on December 14, 2018, Biomx Inc employs approximately 20 people. The company operates within the health care sector, specifically in biotechnology, and is listed on financial markets under the ISIN US09090D5095. Biomx Inc is committed to advancing phage therapy as a novel treatment approach for microbiome-related disorders, with a focus on both therapeutic and preventive applications. The firm's research and development efforts aim to provide targeted solutions for complex bacterial interactions within the human microbiome. Biomx Inc's operations are based in Ness Ziona, Israel, and the company continues to develop its pipeline of phage-based treatments for various medical conditions.

Frequently asked questions about Biomx

6 analysts currently rate the Biomx stock: 0 recommend buying, 3 holding and 3 selling.

Converted at the current exchange rate, the Biomx share trades at 0.26 EUR (0.29 USD).

The revenue cannot currently be calculated for Biomx.

The expected profit of Biomx is -89.51 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Biomx is currently -0.05. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Biomx stock.

The P/S cannot be calculated for Biomx currently.

The Eulerpool Quality Score for Biomx is 2/10.

The ISIN of Biomx is US09090D5095. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Biomx is A2P9A0. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Biomx is PHGE. The ticker symbol is used to trade Biomx shares on the stock exchange.

Fair ValueTerminal
0.24 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website
Country
Israel
Currency
USD
Initial public offering
Dec 14, 2018
ISIN
US09090D5095
Cusip
09090D103
Sedol
BKSSZJ9
Market capitalization
52-Week Range
PEG
0.01
P/E ratio
P/Ee 2026
-0.05
P/Ee 2027
-0.05
P/Ee 2028
-0.68
P/Ee 2029
-0.10
P/Se
—
EV/EBIT
0.09
P/B Ratio
0.02
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-27,014.18 %
Last updated Oct 19, 2026, 3:03 AM

Biomx Ticker

AMEX · PHGE

All fundamentals and in-depth analysis of Biomx

Our stock analysis for Biomx stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biomx. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.